<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662017000100012</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Diferencias en las concentraciones de ácido úrico en pacientes hipertensos, normotensos y prehipertensos]]></article-title>
<article-title xml:lang="en"><![CDATA[Differences in levels of uric acid in hypertensive, normotensive and prehypertensive patients]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rubio-Guerra]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Portillo-Muñoz]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lozano-Nuevo]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas-Ayala]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-López]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales-López]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Unidad de Investigación Clínico-Metabólica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Laboratorio Clínico Laboratorio Clínico ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,Secretaría de Salud de la Ciudad de México Hospital General Ticomán ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af4">
<institution><![CDATA[,Mexican Group for Basic and Clinical Research in Internal Medicine, AC  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2017</year>
</pub-date>
<volume>33</volume>
<numero>1</numero>
<fpage>12</fpage>
<lpage>17</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662017000100012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662017000100012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662017000100012&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  ANTECEDENTES: la prehipertensión es una condición que aumenta el riesgo de padecer hipertensión arterial. Las concentraciones séricas elevadas de ácido úrico se asocian con hipertensión arterial y dificultan su control.  OBJETIVO: evaluar las concentraciones circulantes de ácido úrico en pacientes prehipertensos en comparación con las de sujetos normotensos e hipertensos.  MATERIAL Y MÉTODO: estudio clínico transversal en el que de enero a junio de 2016 las concentraciones séricas de ácido úrico se determinaron por método enzimático en pacientes con prehipertensión (de acuerdo con los criterios del JNC VII), así como en sujetos normotensos y sujetos hipertensos. Los métodos estadísticos usados fueron ANOVA y prueba exacta de Fisher.  RESULTADOS:  se incluyeron 90 pacientes con prehipertensión, 90 sujetos normotensos y 90 sujetos hipertensos. Encontramos que el grupo de prehipertensos tuvo valores significativamente mayores de ácido úrico que los normotensos (6.24±1.5 mg/dL vs 5.4±1.2 mg/dL, p=0.000206), mientras que aunque los valores en hipertensos fueron superiores (6.7±2 mg/dL), no alcanzaron significación estadística con los prehipertensos (p=0.99). Encontramos asociación significativa entre hiperuricemia con prehipertensión (p=0.015 IC 95%; 1.18-3.99).  CONCLUSIONES:  los pacientes prehipertensos mostraron concentraciones de ácido úrico superiores a las de los normotensos y aunque los valores mencionados fueron menores que en los hipertensos, esto no fue significativo. La hiperuricemia puede contribuir, al menos en parte, a mayor progresión hacia hipertensión arterial observada en los prehipertensos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  BACKGROUND: Prehypertension increases the risk of hypertension, serum uric acid levels are also associated with increased risk of hypertension. Increased levels of resistin and/or decreased levels of adiponectin are associated with cardiovascular mortality and the development of hypertension.  OBJECTIVE: To evaluate uric acid serum levels in normotensive, prehypertensive and hypertensive patients.  MATERIAL AND METHOD:  A clinical, cross-sectional study was made from January to June 2016 in which circulating levels of uric acid were measured (enzymatic method) in normotensive, prehypertensive and hypertensive patients. Statistical analysis was performed with ANOVA and Fisher test.  RESULTS: Ninety normotensive, 90 prehypertensive and 90 hypertensive patients were included. Prehypertensive patients have significantly greater levels of uric acid than normotensive subjects (6.24±1.5 mg/dL vs 5.4±1.2 mg/dL, p=0.000206). We also observed that hypertensive patients had increased, although non-significantly, values of uric acid than prehypertensive subjects (6.7±2 mg/dL, p=0.99). We also found a significantly association between hyperuricemia and prehypertension (p=0.015 IC 95%; 1.18-3.99).  CONCLUSIONS: Prehypertensive patients had greater levels of uric acid when compared with normotensive subjects, this may explain why prehypertensive patients shown increased risk for hypertension than normotensive patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[ácido úrico]]></kwd>
<kwd lng="es"><![CDATA[prehipertensión]]></kwd>
<kwd lng="es"><![CDATA[hipertensión arterial]]></kwd>
<kwd lng="en"><![CDATA[uric acid]]></kwd>
<kwd lng="en"><![CDATA[prehypertension]]></kwd>
<kwd lng="en"><![CDATA[hypertension]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metabolic syndrome, diabetes, and hyperuricemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hsieh]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Opin Rheumatol]]></source>
<year>2013</year>
<volume>25</volume>
<page-range>210</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Circulating levels of uric acid and risk for metabolic syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubio-Guerra]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Morales-Lopez]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Garro-Almendaro]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Diabetes Rev]]></source>
<year>2016</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubio-Guerra]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[¿Se debe tratar la prehipertensión?]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio]]></surname>
<given-names><![CDATA[AF.]]></given-names>
</name>
</person-group>
<source><![CDATA[Controversias en síndrome metabólico]]></source>
<year>2011</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Alfil]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cardiac and vascular consequences of pre-hypertension in youth]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urbina]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Khoury]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[McCoy]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Hypertens (Greenwich)]]></source>
<year>2011</year>
<volume>13</volume>
<page-range>332-342.</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Uric acid and the development of hypertension the normative aging study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perlstein]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Gumieniak]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
</person-group>
<source><![CDATA[Hypertension]]></source>
<year>2006</year>
<volume>48</volume>
<page-range>1031-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Predictors of progression from prehypertension to hypertension among rural Chinese adults results from Liaoning Province]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Cardiovasc Prev Rehabil]]></source>
<year>2010</year>
<volume>17</volume>
<page-range>217-22</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Serum uric acid and target organ damage in essential hypertension]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ofori]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Odia]]></surname>
<given-names><![CDATA[OJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Vasc Health Risk Manag]]></source>
<year>2014</year>
<volume>10</volume>
<page-range>253-61</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Serum levels of circulating soluble adhesion molecules and nitrites in patients with prehypertension]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubio-Guerra]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas-Robles]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez-Cuenca]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano-Nuevo]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Escalante-Acosta]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Hyper Res]]></source>
<year>2013</year>
<volume>1</volume>
<page-range>23-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Serum uric acid and prehypertension among adults free of cardiovascular diseases and diabetes baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lotufo]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Baena]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
<name>
<surname><![CDATA[Bensenor]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
</person-group>
<source><![CDATA[Angiology]]></source>
<year>2016</year>
<volume>67</volume>
<page-range>180-6</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Hyperuricemia and uncontrolled hypertension in treated hypertensive patients K-MetS Study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2016</year>
<volume>95</volume>
<page-range>4177</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A pilot study on the impact of a low fructose diet and allopurinol on clinic blood pressure among overweight and prehypertensive subjects a randomized placebo controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Madero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Castellanos]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
<name>
<surname><![CDATA[Jalal]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[VillalobosMartín]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Soc Hypertens]]></source>
<year>2015</year>
<volume>9</volume>
<page-range>837-44</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack a randomised controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Walters]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[McArthur]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Heart]]></source>
<year>2014</year>
<volume>100</volume>
<page-range>1085-92</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Seo]]></surname>
<given-names><![CDATA[YI]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[YW]]></given-names>
</name>
</person-group>
<source><![CDATA[J Korean Med Sci]]></source>
<year>2014</year>
<volume>29</volume>
<page-range>1077-81</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients a cohort study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Larsen]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Pottegård]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lindegaard]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Hallas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Med]]></source>
<year>2016</year>
<volume>129</volume>
<page-range>299-306</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of febuxostat, a xanthine oxidase inhibitor, on cardiovascular risk in hyperuricemic patients with hypertension a prospective, open-label, pilot study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nagao]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hirayama]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Drug Investig]]></source>
<year>2015</year>
<volume>35</volume>
<page-range>823-31</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
